Prognostic significance of (I8) F-fluorodeoxyglucose - Positron emission tomography after treatment in patients with limited stage small cell lung cancer

Clinical Medicine and Research

Volumn 6, Issue 2, 2008, Pages 72-77

  Onitilo, Adedayo A ^a   Engel, Jessica M ^a   Demos, Jennifer M ^a   Mukesh, Bickol ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

18EF FDG.PET; Limited stage small cell lung cancer; Prognosis; Recurrence; Treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LUNG SMALL CELL CANCER; LUNG SURGERY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; THREE DIMENSIONAL IMAGING; TIME; ADULT; AGED; FEMALE; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; SCINTISCANNING; SMALL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 58149148190     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2008.797     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society, 2007. Available at: http://www.cancer.org/ docroot/STT/stt_0_2007.asp?sitearea=STT&level=1. Accessed July 11, 2008.
2. Chute CG, Greenberg ER, Baron J, Korson R, Baker J, Yates J. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985;56:2107-2111.
3. Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, Bull R. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease? Lung Cancer 2002:37:271-276.
4. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991;99:1425-1432.
5. Johnson BE, Ihde DC, Bunn PA, Becker B, Walsh T, Weinstein ZR, Matthews MJ, Whang-Peng J, Makuch RW, Johnston-Early A. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med 1985;103:430-438.
6. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 1995;13:1215-1220.
7. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, Eaton W, Zimmer B, Green M. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989;7:344-354.
8. Avril NA, Weber W. Monitoring cancer treatments using [18F] fluorodeoxyglucose positron emission tomography. In: Govindan R, ed. American Society of Clinical Oncology Educational Book: 43rd Annual Meeting. Alexandria, VA: American Society of Clinical Oncology; 2007: 15-19.
9. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-332.
10. Israel O, Kuten A. Early detection of cancer recurrence: 18 F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med 2007;48(suppl 1):28S-35S.
11. Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 2005;104:2650-2657.
12. Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol 2004;22:127-132.
13. Buatti J, Yao M, Dornfeld K, Skwarchuk M, Hoffman HT, Funk GF, Smith RB, Graham SM, Menda Y, Graham MM. Efficacy of IMRT in head and neck cancer as monitored by post-RT PET scans. Int J Radiat Biol Phys 2003;57(2 suppl):S305.
14. Chin R Jr, McCain TW, Miller AA, Dunagan DP, Acostamadiedo J, Douglas Case L, Harkness BA, Adler LP, Haponik EF. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002;37:1-6.
15. Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Daugaard G, Hansen HH. PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer 2006;54:41-49.
16. Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007;30:45-50.
17. Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, Henke M, Moser E, Nitzsche E. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001;28:483-488.
18. Zhao DS, Valdivia AY, Li Y, Blaufox MD. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 2002; 32:272-275.
19. 18F] FDG-PET imaging in small cell lung cancer. Eur J Nucl Med 2003;30:78-84.